Seeing cancer in a way that has never been seen before
Using full-length RNA sequencing from blood to detect novel biomarkers that have the potential to revolutionise cancer medicine.
Seeing cancer in a way that has never been seen before
Using full-length RNA sequencing from blood to detect novel biomarkers that have the potential to revolutionise cancer medicine.
Seeing cancer in a way that has never been seen before
Using full-length RNA sequencing from blood to detect novel biomarkers that have the potential to revolutionise cancer medicine.
Welcome to Wobble Genomics
Wobble Genomics has developed a novel diagnostic platform that can detect low abundance full-length RNA from whole blood to provide more accurate information on the status of disease in cancer patients.
Our Level-Up technology allows us to see into a world of RNA that was previously hidden. By combining our Level-Up and TAMA technologies with long-read RNA sequencing, we have been able to see an astonishingly wide range of RNA sequences that were completely unknown until now. These newly discovered RNA have the potential to allow for disease detection and monitoring that could improve cancer care for everyone.
Welcome to Wobble Genomics
Wobble Genomics has developed a novel diagnostic platform that can detect low abundance full-length RNA from whole blood to provide more accurate information on the status of disease in cancer patients.
Our Level-Up technology allows us to see into a world of RNA that was previously hidden. By combining our Level-Up and TAMA technologies with long-read RNA sequencing, we have been able to see an astonishingly wide range of RNA sequences that were completely unknown until now. These newly discovered RNA have the potential to allow for disease detection and monitoring that could improve cancer care for everyone.
Welcome to Wobble Genomics
Wobble Genomics has developed a novel diagnostic platform that can detect low abundance full-length RNA from whole blood to provide more accurate information on the status of disease in cancer patients.
Our Level-Up technology allows us to see into a world of RNA that was previously hidden. By combining our Level-Up and TAMA technologies with long-read RNA sequencing, we have been able to see an astonishingly wide range of RNA sequences that were completely unknown until now. These newly discovered RNA have the potential to allow for disease detection and monitoring that could improve cancer care for everyone.
Latest News
-
Wobble Genomics, a biotechnology company focused on improving cancer outcomes through better diagnosis and therapy selection, presents new data at the 2025 San Antonio Breast Cancer Symposium (SABCS), (December 9-12), in San Antonio, Texas. The data demonstrates the ability to accurately detect HER2 expression in breast cancer, both in solid tumour biopsies and blood samples.
Wobble Genomics Presents Latest Data at SABCS: Confirming Platform's Ability To Determine Detailed Profiling of HER2 Status in Tissue and Blood.
Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an enhanced liquid biopsy platform for sensitive detection of low-abundance RNA.
Latest News
-
Wobble Genomics, a biotechnology company focused on improving cancer outcomes through better diagnosis and therapy selection, presents new data at the 2025 San Antonio Breast Cancer Symposium (SABCS), (December 9-12), in San Antonio, Texas. The data demonstrates the ability to accurately detect HER2 expression in breast cancer, both in solid tumour biopsies and blood samples.
-
Wobble Genomics Presents Latest Data at SABCS: Confirming Platform's Ability To Determine Detailed Profiling of HER2 Status in Tissue and Blood.
Latest News
-
Wobble Genomics, a biotechnology company focused on improving cancer outcomes through better diagnosis and therapy selection, presents new data at the 2025 San Antonio Breast Cancer Symposium (SABCS), (December 9-12), in San Antonio, Texas. The data demonstrates the ability to accurately detect HER2 expression in breast cancer, both in solid tumour biopsies and blood samples.
-
Wobble Genomics Presents Latest Data at SABCS: Confirming Platform's Ability To Determine Detailed Profiling of HER2 Status in Tissue and Blood.
-
Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an enhanced liquid biopsy platform for sensitive detection of low-abundance RNA.
